Highlighted Post-Market Laggard: Keryx Biopharmaceuticals (KERX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Keryx Biopharmaceuticals ( KERX) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Keryx Biopharmaceuticals as such a stock due to the following factors:

  • KERX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $61.1 million.
  • KERX is down 3% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in KERX with the Ticky from Trade-Ideas. See the FREE profile for KERX NOW at Trade-Ideas

More details on KERX:

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. Currently there are 8 analysts that rate Keryx Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

The average volume for Keryx Biopharmaceuticals has been 2.3 million shares per day over the past 30 days. Keryx has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 4.36 and a short float of 22% with 4.21 days to cover. Shares are up 4.1% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)